Gabe is based out of our New York office. He has over 15 years of experience advising clients in the life sciences industry on intellectual property matters, particularly in the areas of patent preparation, prosecution, and strategic counseling. He has advised biopharmaceutical, biomedical device, pharmaceutical, contract manufacturing, and molecular diagnostic companies of all sizes and stages of growth, ranging from startup companies through global corporations. Gabe also has extensive experience counseling universities and research institutes on a range of patent matters. In addition, Gabe has significant in-house experience at a global biopharmaceutical corporation as a seconded patent attorney where he developed patent portfolios covering FDA-approved biologics and pharmaceutical products.
Gabe also has substantial experience in conducting patentability studies, freedom-to-operate analyses, and due diligence, as well as providing legal opinions addressing patentability, clearance, and validity inquiries. Gabe also has assisted with a variety of patent-related administrative proceedings before the USPTO, including inter-partes reviews and interferences, as well as opposition proceedings before the European Patent Office. Gabe has provided litigation support in generic drug patent disputes arising under the Hatch-Waxman Act, and has provided counseling on biosimilars.
Gabe’s experience spans a wide range of biotechnology areas, including therapeutic antibodies and proteins, pharmaceuticals, stem cells, genome-editing technology, bioprocessing, gene therapy, medical diagnostics, vaccines, nucleic acid-based therapies, and biomedical devices.
Gabe’s doctoral research focused on the regulation and biosynthesis of intracellular bacterial energy storage biopolymers and their application as bioplastics.
Gabe is a co-inventor on US Patent No. 6,835,820, which relates to his doctoral research. Gabe has also co-authored numerous scientific and legal publications and regularly moderates and/or presents on IP-related topics.